Rescaled Tariff Regression for EQ-5D-5L Health State Valuation: An Equivalent Alternative to the Nonparametric Crosswalk
Author(s)
Sean P. Gavan, BA, MSc, PhD.
Manchester Centre for Health Economics, The University of Manchester, Manchester, United Kingdom.
Manchester Centre for Health Economics, The University of Manchester, Manchester, United Kingdom.
OBJECTIVES: Introduce the rescaled tariff regression for EQ-5D-5L health state valuation and demonstrate its equivalence with the nonparametric crosswalk.
METHODS: The rescaled tariff regression and the nonparametric crosswalk methods were applied to a stylised example using the simplest case possible to demonstrate equivalence. Both methods were then applied to estimate EQ-5D-5L state values from EQ-5D-3L value sets for three countries (United Kingdom, the Netherlands, Spain). The rescaled tariff regression converted the original three-level value set regression parameters comprising dichotomous independent variables into regression parameters for the five-level version. The state valuations for twenty-eight common EQ-5D-5L response profiles were then estimated by the rescaled tariff regression and nonparametric crosswalk to assess equivalence using value sets from the three different countries.
RESULTS: The stylised example demonstrated that the rescaled tariff regression and nonparametric crosswalk estimated identical health state values. When applied to EQ-5D-3L value sets, the rescaled tariff regression demonstrated that a level-two response and level-three response using the EQ-5D-3L, respectively, corresponded with a level-three response and level-five response using the EQ-5D-5L. The analysis of twenty-eight common EQ-5D-5L response profiles produced identical health state values for the United Kingdom, the Netherlands, and Spain’s value sets under both the rescaled tariff regression and nonparametric crosswalk.
CONCLUSIONS: The rescaled tariff regression provides improved transparency than the nonparametric crosswalk when estimating EQ-5D-5L health state values anchored to EQ-5D-3L value sets. Both methods may be used in combination for jurisdictions where new EQ-5D-5L valuation studies are not planned but a relevant EQ-5D-3L value set is available.
METHODS: The rescaled tariff regression and the nonparametric crosswalk methods were applied to a stylised example using the simplest case possible to demonstrate equivalence. Both methods were then applied to estimate EQ-5D-5L state values from EQ-5D-3L value sets for three countries (United Kingdom, the Netherlands, Spain). The rescaled tariff regression converted the original three-level value set regression parameters comprising dichotomous independent variables into regression parameters for the five-level version. The state valuations for twenty-eight common EQ-5D-5L response profiles were then estimated by the rescaled tariff regression and nonparametric crosswalk to assess equivalence using value sets from the three different countries.
RESULTS: The stylised example demonstrated that the rescaled tariff regression and nonparametric crosswalk estimated identical health state values. When applied to EQ-5D-3L value sets, the rescaled tariff regression demonstrated that a level-two response and level-three response using the EQ-5D-3L, respectively, corresponded with a level-three response and level-five response using the EQ-5D-5L. The analysis of twenty-eight common EQ-5D-5L response profiles produced identical health state values for the United Kingdom, the Netherlands, and Spain’s value sets under both the rescaled tariff regression and nonparametric crosswalk.
CONCLUSIONS: The rescaled tariff regression provides improved transparency than the nonparametric crosswalk when estimating EQ-5D-5L health state values anchored to EQ-5D-3L value sets. Both methods may be used in combination for jurisdictions where new EQ-5D-5L valuation studies are not planned but a relevant EQ-5D-3L value set is available.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
MSR182
Topic
Economic Evaluation, Health Technology Assessment, Methodological & Statistical Research
Topic Subcategory
PRO & Related Methods
Disease
No Additional Disease & Conditions/Specialized Treatment Areas